Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma... Cardiovasc Intervent Radiol (2017) 40:1372–1382 DOI 10.1007/s00270-017-1655-8 CLINICAL INVESTIGATION VENOUS INTERVENTIONS Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus 1,4 2 3 1 • • • Bin Qiu Kai Li Xiaoqun Dong Fu-Quan Liu Received: 10 December 2016 / Accepted: 18 April 2017 / Published online: 9 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract The symptoms of portal hypertension were well relieved. Purpose In patients with hepatocellular carcinoma (HCC), Variceal bleeding was successfully controlled and termi- limited therapeutic options are available for portal hyper- nated in 100% of patients, with a recurrence rate of 39.2% tension resulted from portal vein tumor thrombus (PVTT). in 12 months. Refractory ascites/hydrothorax was con- We aimed to determine safety and efficacy of TIPS for trolled partially or completely in 92.9% of patients during treatment of symptomatic portal hypertension in HCC with 1 month after TIPS, with a recurrence rate of 17.9% in PVTT. 12 months. Survival rate at 6, 12, 24, and 36 months was Methods We evaluated clinical characteristics of 95 75.8, 52.7, 26.4, and 3.3%, respectively. No unexpected patients with HCC and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Loading next page...
 
/lp/springer_journal/transjugular-intrahepatic-portosystemic-shunt-for-portal-hypertension-MRZ34ZnBEq

References (32)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
DOI
10.1007/s00270-017-1655-8
pmid
28488102
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1372–1382 DOI 10.1007/s00270-017-1655-8 CLINICAL INVESTIGATION VENOUS INTERVENTIONS Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus 1,4 2 3 1 • • • Bin Qiu Kai Li Xiaoqun Dong Fu-Quan Liu Received: 10 December 2016 / Accepted: 18 April 2017 / Published online: 9 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract The symptoms of portal hypertension were well relieved. Purpose In patients with hepatocellular carcinoma (HCC), Variceal bleeding was successfully controlled and termi- limited therapeutic options are available for portal hyper- nated in 100% of patients, with a recurrence rate of 39.2% tension resulted from portal vein tumor thrombus (PVTT). in 12 months. Refractory ascites/hydrothorax was con- We aimed to determine safety and efficacy of TIPS for trolled partially or completely in 92.9% of patients during treatment of symptomatic portal hypertension in HCC with 1 month after TIPS, with a recurrence rate of 17.9% in PVTT. 12 months. Survival rate at 6, 12, 24, and 36 months was Methods We evaluated clinical characteristics of 95 75.8, 52.7, 26.4, and 3.3%, respectively. No unexpected patients with HCC and

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: May 9, 2017

There are no references for this article.